Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rheumatic Diseases | 11 | 2021 | 2675 | 1.58 | Why? |
| Antirheumatic Agents | 8 | 2021 | 3023 | 0.95 | Why? |
| Rheumatology | 6 | 2021 | 1213 | 0.89 | Why? |
| Granulomatosis with Polyangiitis | 1 | 2018 | 161 | 0.61 | Why? |
| Glucocorticoids | 8 | 2021 | 4431 | 0.50 | Why? |
| Arthritis, Rheumatoid | 4 | 2021 | 2043 | 0.46 | Why? |
| Massachusetts | 2 | 2020 | 1279 | 0.30 | Why? |
| Information Dissemination | 2 | 2020 | 2986 | 0.29 | Why? |
| Registries | 6 | 2021 | 12327 | 0.28 | Why? |
| Rituximab | 4 | 2018 | 1096 | 0.25 | Why? |
| Lymphoma | 2 | 2017 | 522 | 0.24 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.23 | Why? |
| Respiration, Artificial | 5 | 2021 | 22116 | 0.20 | Why? |
| Receptors, Phospholipase A2 | 1 | 2019 | 14 | 0.20 | Why? |
| Retroperitoneal Fibrosis | 1 | 2018 | 20 | 0.19 | Why? |
| Polyarteritis Nodosa | 1 | 2018 | 25 | 0.19 | Why? |
| Temporal Arteries | 1 | 2018 | 35 | 0.18 | Why? |
| Glomerulonephritis, Membranous | 1 | 2019 | 71 | 0.18 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.18 | Why? |
| Neoplasms, Plasma Cell | 1 | 2017 | 83 | 0.18 | Why? |
| Subclavian Artery | 1 | 2017 | 21 | 0.17 | Why? |
| Prednisone | 2 | 2020 | 652 | 0.17 | Why? |
| Takayasu Arteritis | 1 | 2017 | 83 | 0.16 | Why? |
| Interinstitutional Relations | 1 | 2018 | 170 | 0.16 | Why? |
| Education, Medical, Graduate | 2 | 2020 | 2082 | 0.14 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 235 | 0.14 | Why? |
| Plasma Cells | 1 | 2017 | 464 | 0.14 | Why? |
| Mentors | 1 | 2018 | 372 | 0.13 | Why? |
| Rheumatologists | 1 | 2018 | 346 | 0.13 | Why? |
| Immune System Diseases | 1 | 2017 | 410 | 0.13 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.13 | Why? |
| Testis | 1 | 2018 | 566 | 0.12 | Why? |
| Immunosuppressive Agents | 3 | 2021 | 6331 | 0.12 | Why? |
| Arterial Occlusive Diseases | 1 | 2017 | 363 | 0.12 | Why? |
| Immunoglobulin G | 5 | 2019 | 21571 | 0.11 | Why? |
| Data Collection | 1 | 2021 | 1769 | 0.11 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 1454 | 0.11 | Why? |
| Drug Hypersensitivity | 1 | 2017 | 401 | 0.10 | Why? |
| Janus Kinase Inhibitors | 3 | 2020 | 682 | 0.10 | Why? |
| Autoimmune Diseases | 2 | 2020 | 1996 | 0.10 | Why? |
| Humans | 30 | 2021 | 930598 | 0.09 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.09 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.09 | Why? |
| Immunologic Factors | 3 | 2020 | 4206 | 0.09 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.08 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.08 | Why? |
| Vascular Diseases | 1 | 2016 | 846 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Aged | 12 | 2021 | 215776 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
| Male | 17 | 2021 | 367725 | 0.07 | Why? |
| Schools | 1 | 2021 | 4187 | 0.07 | Why? |
| Odds Ratio | 3 | 2021 | 5861 | 0.07 | Why? |
| Female | 16 | 2021 | 380317 | 0.07 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.07 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.07 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.07 | Why? |
| Internet | 1 | 2021 | 6204 | 0.06 | Why? |
| Patient Acceptance of Health Care | 1 | 2021 | 5002 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Cooperative Behavior | 2 | 2021 | 1216 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| United States | 4 | 2021 | 46150 | 0.05 | Why? |
| Education, Distance | 1 | 2020 | 4956 | 0.05 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.05 | Why? |
| Epididymis | 1 | 2018 | 23 | 0.05 | Why? |
| Retroperitoneal Space | 1 | 2018 | 68 | 0.05 | Why? |
| Wisconsin | 1 | 2021 | 607 | 0.05 | Why? |
| Thrombocytosis | 1 | 2017 | 21 | 0.04 | Why? |
| Adult | 10 | 2021 | 244371 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2021 | 481 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| School Teachers | 1 | 2021 | 345 | 0.04 | Why? |
| Sarcoidosis | 1 | 2020 | 271 | 0.04 | Why? |
| Arthralgia | 1 | 2018 | 173 | 0.04 | Why? |
| Hematuria | 1 | 2018 | 284 | 0.04 | Why? |
| Leukocytosis | 1 | 2018 | 280 | 0.04 | Why? |
| Cyclophosphamide | 1 | 2018 | 387 | 0.04 | Why? |
| Magnetic Resonance Angiography | 1 | 2017 | 282 | 0.04 | Why? |
| Curriculum | 2 | 2020 | 3083 | 0.04 | Why? |
| Biological Products | 2 | 2020 | 2331 | 0.04 | Why? |
| Bias | 1 | 2020 | 1109 | 0.04 | Why? |
| Purines | 1 | 2020 | 816 | 0.04 | Why? |
| Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 213 | 0.03 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.03 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.03 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.03 | Why? |
| Erythema | 1 | 2017 | 400 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.03 | Why? |
| Renal Replacement Therapy | 1 | 2021 | 1530 | 0.03 | Why? |
| Sulfonamides | 1 | 2020 | 1294 | 0.03 | Why? |
| Program Development | 1 | 2018 | 1089 | 0.03 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Pain | 1 | 2018 | 1084 | 0.03 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.03 | Why? |
| Anemia | 1 | 2017 | 789 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2020 | 1881 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.02 | Why? |
| Social Media | 2 | 2021 | 5798 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Rural Population | 1 | 2021 | 2408 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Internationality | 1 | 2021 | 3297 | 0.02 | Why? |
| Anaphylaxis | 1 | 2017 | 940 | 0.02 | Why? |
| Exanthema | 1 | 2017 | 1097 | 0.02 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.02 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Electronic Health Records | 1 | 2017 | 3492 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.02 | Why? |
| Inflammatory Bowel Diseases | 1 | 2020 | 3209 | 0.02 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.02 | Why? |
| Students | 1 | 2021 | 5255 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.01 | Why? |
| Gastrointestinal Diseases | 1 | 2017 | 2580 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.01 | Why? |
| Fever | 1 | 2018 | 7795 | 0.01 | Why? |
| Tomography, X-Ray Computed | 2 | 2018 | 25144 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.01 | Why? |
| Skin Diseases | 1 | 2017 | 2509 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Travel | 1 | 2017 | 7220 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.01 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.01 | Why? |
Wallace's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(156)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(180)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_